5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1285-1291

  Izbicka, Elzbieta ^a   Macdonald, John R ^b   Davidson, Karen ^a   Lawrence, Richard A ^a   Gomez, Lionel ^a   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

^b GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

5,6 dihydro 5' azacytidine; Androgen receptor; Cancer; Cytosine DNA methyltransferase; Hormone sensitivity; Prostate

Indexed keywords

5,6 DIHYDROAZACITIDINE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; DNA METHYLTRANSFERASE; HYDROXYFLUTAMIDE;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL DIVISION; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLUTAMIDE; HUMANS; MALE; PROSTATIC NEOPLASMS; SITE-SPECIFIC DNA METHYLTRANSFERASE (CYTOSINE-SPECIFIC); TUMOR CELLS, CULTURED;

EID: 0032991339     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jones PA: DNA methylation errors and cancer. Cancer Res 56: 2463-2467, 1996.
2. Trapman J and Brinkmann AO: Mutations in the androgen receptor. Ann NY Acad Sci 684: 85-93, 1993.
3. Harmon D, Vogelzang N, Roboz J, Goutsou M, Antman K, Coughlin K, and Green MR: Dihydro-5-azacytidine (DHAC) in malignant mesothelioma (Meso) using serum hyaluronic acid (SHA) as tumor marker: a Phase II trial of the CALGB. ASCO Proc 10: 351, 1991.
4. Jarrard D, Nassif N, Kinoshita H, Chang C, and Issacs W: Analysis of androgen receptor CpG island methylation in metastatic prostate cancer cell lines. In: DNA methylation, imprinting, and the epigenetics of cancer, Fajardo, Puerto Rico, 1997, pp. A20
5. Salman M and Chamness G: A potential radioiodinated ligand for androgen receptor: 7alpha-methyl-17alpha-(2'-(E)-iodovinyl)-19-nortestosterone. J Med Chem 34: 1019-1024, 1991.
6. Issa JP, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, Hamilton SR, and Baylin SB: Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst 85: 1235-1240, 1993.
7. Mossman T: Rapid colorimetric assay fof'cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
8. Ferguson AT, Lapidus RG, Baylin SB, and Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55: 2279-2283, 1995.
9. Vogelzang NJ, Hamdon JE, Harmon DC, Antman KN, Carson JM, Suzuki Y, Citron ML, and Green MR: Dihydro-5-azacytidine in malignant mesothelioma. Cancer 79: 2237-2242, 1997.
10. Veldscholte J, Ris-Stalpers C, Kuiper G, Jenster G, Berrevoets C, Classen E, van Rooij H, Brinkmann A and Mulder E: A mutation in the ligand-binding domain of the androgen receptor of human LNCaP cells affect steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 173: 534-540, 1990.
11. Wilding G, Chen M and Gelmann E: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14: 103-115, 1989.
12. Tilley W, Wilson C, Marcelli M and McPhaul M: Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50: 5382-5386, 1990.
13. Gabbara S and Bhagwat A: The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem J 307: 87-92, 1995.
14. Izbicka E, Davidson K, Yoneda T, Williams P and Von Hoff DD: Cytidine analogs upregulate androgen receptor expression and induce apoptosis in human prostate cancer cells in vitro. J Bone Miner Res 11: 483, 1996.
15. Graff J, Herman J, Lapidus R, Chopra H, Xu R, Jarrard DF, Issacs WB, Pitha PM, Davidson NE, and Baylin SE: E-Cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55: 5195-5199, 1995.
16. Schroeder M and Mass MJ: CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem Biophys Res Comm 235: 403-406, 1997.
17. Kissil J, Feinstein E, Cohen O, Jones P, Tsai Y, Knowles M, Eydmann M, and Kimchi A: DAP-kinase loss of expression in variuos carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene 15: 403-407, 1997.